Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 64
Filter
Add more filters










Publication year range
1.
J Med Case Rep ; 14(1): 222, 2020 Nov 17.
Article in English | MEDLINE | ID: mdl-33198808

ABSTRACT

BACKGROUND: The association between non seminomatous germ cell tumors (GCTs) and hematological malignancies of rare lineage has been described in the literature. In some of these cases there is evidence that the leukemia derives from a pluripotent primitive clone present in the original germ cell tumor. CASE PRESENTATION: We present a highly unusual case of a 23-year-old man of South Asian origin with a history of Klinefelter's syndrome who initially developed mediastinal non seminomatous GCT. Following treatment with surgery and standard chemotherapy he went on to develop three different hematological malignancies of distinct lineages in sequential fashion over a short time period. Despite treatment with multiple intensive chemotherapy regimens and a matched unrelated donor allogeneic stem cell transplant, he died 41 months after initial diagnosis of his GCT and 10 months after the first diagnosis of hematological malignancy. CONCLUSIONS: This is an extreme case that highlights the pluripotency and aggressiveness of these GCT-derived hematological malignancies, and the need for novel therapeutic approaches.


Subject(s)
Hematologic Neoplasms , Mediastinal Neoplasms , Neoplasms, Germ Cell and Embryonal , Testicular Neoplasms , Adult , Hematologic Neoplasms/complications , Hematologic Neoplasms/therapy , Humans , Male , Mediastinal Neoplasms/therapy , Neoplasms, Germ Cell and Embryonal/therapy , Testicular Neoplasms/surgery , Young Adult
3.
Neurology ; 66(4): 602-4, 2006 Feb 28.
Article in English | MEDLINE | ID: mdl-16505324

ABSTRACT

LY450139 dihydrate, a gamma-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta.


Subject(s)
Alanine/analogs & derivatives , Alzheimer Disease/drug therapy , Azepines/therapeutic use , Endopeptidases/metabolism , Alanine/pharmacokinetics , Alanine/therapeutic use , Amyloid Precursor Protein Secretases , Aspartic Acid Endopeptidases , Azepines/pharmacokinetics , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/therapeutic use , Humans , Placebos
4.
Drug Discov Today ; 6(9): 459-462, 2001 May 01.
Article in English | MEDLINE | ID: mdl-11344030
5.
J Neurochem ; 76(1): 173-81, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11145990

ABSTRACT

Converging lines of evidence implicate the beta-amyloid peptide (Ass) as causative in Alzheimer's disease. We describe a novel class of compounds that reduce A beta production by functionally inhibiting gamma-secretase, the activity responsible for the carboxy-terminal cleavage required for A beta production. These molecules are active in both 293 HEK cells and neuronal cultures, and exert their effect upon A beta production without affecting protein secretion, most notably in the secreted forms of the amyloid precursor protein (APP). Oral administration of one of these compounds, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, to mice transgenic for human APP(V717F) reduces brain levels of Ass in a dose-dependent manner within 3 h. These studies represent the first demonstration of a reduction of brain A beta in vivo. Development of such novel functional gamma-secretase inhibitors will enable a clinical examination of the A beta hypothesis that Ass peptide drives the neuropathology observed in Alzheimer's disease.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Brain/metabolism , Dipeptides/administration & dosage , Endopeptidases/metabolism , Administration, Oral , Alzheimer Disease/drug therapy , Alzheimer Disease/genetics , Amyloid Precursor Protein Secretases , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Aspartic Acid Endopeptidases , Brain/cytology , Brain/drug effects , Cells, Cultured , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Endopeptidases/drug effects , Enzyme Inhibitors/administration & dosage , Female , Humans , Injections, Subcutaneous , Kidney/cytology , Kidney/drug effects , Kidney/metabolism , Male , Mice , Mice, Transgenic , Neurons/cytology , Neurons/drug effects , Neurons/metabolism , Peptide Fragments/metabolism
6.
Neuroimmunomodulation ; 7(3): 147-52, 2000.
Article in English | MEDLINE | ID: mdl-10754402

ABSTRACT

Chronic neurodegeneration in the brains of Alzheimer's disease (AD) patients may be mediated, at least in part, by the ability of amyloid beta (Abeta) to exacerbate inflammatory pathways in a conformation-dependent manner. In this regard, we previously reported that the Abeta-peptide-mediated potentiation of inflammatory cytokine secretion from interleukin-1beta (IL-1beta)-stimulated human astrocytoma cells was conformation dependent. Other amyloidogenic peptides, such as human amylin, which display similar conformation-dependent neurotoxic effects, may also elicit inflammatory cytokine secretion from glial cells. To test this hypothesis, we compared human and rat amylin for the effects on cytokine production in U-373 MG human astrocytoma cells. Human amylin alone stimulated U-373 MG cells to secrete IL-6 and IL-8 in a concentration-dependent manner with maximum effects seen at 10-25 microM peptide. In addition, human amylin markedly potentiated IL-1beta-stimulated cytokine production with a similar concentration dependence. In contrast, nonamyloidogenic rat amylin modestly stimulated cytokine secretion, either alone or combined with IL-1beta. Aging human amylin resulted in diminished cytokine secretion, probably due to the formation of large, less active aggregates. In agreement with our previous studies using Abeta, extracellular Ca(2+) was necessary for human amylin stimulation of cytokine secretion. Our data suggest that amyloidogenic peptides promote cytokine secretion through similar beta-sheeted secondary-structure- and extracellular-Ca(2+)-dependent mechanisms.


Subject(s)
Alzheimer Disease/metabolism , Amyloid/pharmacology , Astrocytoma/metabolism , Brain Neoplasms/metabolism , Cytokines/metabolism , Neoplasm Proteins/metabolism , Aging/metabolism , Amyloid/chemistry , Amyloid beta-Peptides/chemistry , Animals , Astrocytoma/pathology , Brain Neoplasms/pathology , Calcium/pharmacology , Dose-Response Relationship, Drug , Drug Synergism , Egtazic Acid/pharmacology , Humans , Interleukin-1/pharmacology , Islet Amyloid Polypeptide , Nerve Degeneration , Protein Structure, Secondary , Rats , Recombinant Proteins/pharmacology , Sequence Homology, Amino Acid , Species Specificity , Tumor Cells, Cultured/drug effects
7.
Ann N Y Acad Sci ; 917: 154-64, 2000.
Article in English | MEDLINE | ID: mdl-11268339

ABSTRACT

Neurodegenerative processes in Alzheimer's disease (AD) are thought to be driven, in part, by the deposition of amyloid beta (A beta), a 39-43-aminoacid peptide product resulting from an alternative cleavage of amyloid precursor protein (APP). In addition to its neurotoxic properties, A beta may influence neuropathology by stimulating glial cell cytokine and acute phase protein secretion in affected areas of the brain (e.g., cortex, hippocampus). Using an in vitro human astrocyte model (U-373 MG astrocytoma cells), the effects of A beta treatment on acute phase protein (APP and alpha-1-antichymotrypsin [alpha 1-ACT]) and interleukin-8 (IL-8) were examined. U-373 MG cells secreted increased levels of alpha 1-ACT and neurotrophic/neuroprotective alpha-cleaved APP (alpha APP) after exposure to interleukin-1 beta (IL-1 beta) for 24 hours. A beta treatment resulted in a similar, but modest increase in alpha 1-ACT secretion, a two- to threefold stimulation of IL-8 production, and, conversely, a profound reduction in the levels of secreted alpha APPs. A beta inhibited alpha APP secretion by U-373 MG cells in a concentration- and conformation-dependent manner. Moreover, the reduction in alpha APP secretion was accompanied by an increase in cell-associated APP. Another proinflammatory amyloidogenic peptide, human amylin, similarly affected APP processing in U-373 astrocytoma cells. These data suggest that A beta may contribute to Alzheimer's-associated neuropathology by lowering the production of neuroprotective/neurotrophic alpha APPs. Moreover, the concomitant increase in cell-associated APP may provide increased substrate for the generation of amyloidogenic peptides within astrocytes.


Subject(s)
Alzheimer Disease/immunology , Amyloid beta-Peptides/immunology , Amyloid beta-Protein Precursor/immunology , Cytokines/immunology , Alzheimer Disease/metabolism , Cell Line , Cytokines/metabolism , Humans , Inflammation , Protein Processing, Post-Translational/immunology
8.
Brain Res ; 830(1): 88-93, 1999 May 29.
Article in English | MEDLINE | ID: mdl-10350562

ABSTRACT

Basic fibroblast growth factor (bFGF) has been reported to have neuroprotective properties following excitotoxic, metabolic, and oxidative insults. We report here that another FGF family member, FGF-8 is able to protect rat hippocampal cultures from oxidative stress. The b isoform of FGF-8 protected hippocampal cultures from hydrogen peroxide with an EC50 of approximately 25 ng/ml. In a time course study, using pre-, co-, post-treatment paradigms, we report that bFGF and FGF-8b were neuroprotective when added as a pre-treatment, co-treatment, and even at 2 h post-insult. Using neuronal enriched cultures, we demonstrate that bFGF and FGF-8b neuroprotection partially results from a direct action of the growth factors on neurons. The direct action on neurons may work in concert with normal and FGF-stimulated glial secretion products to give the full FGF protective effect. FGF-8b showed maximal protection at 50 ng/ml, whereas bFGF showed maximal protection at 10 ng/ml. Despite requiring higher concentrations to elicit protection, FGF-8b is able to attain levels of protection equivalent to that of bFGF (attenuation of 75-80% of hydrogen peroxide induced death). We also report that bFGF and FGF-8b are able to protect the human neuroblastoma cell line, SK-N-MC, from peroxide-induced LDH release by 50%. From these studies, we conclude that FGF-8b is another member of the FGF family which may show in vivo efficacy for the treatment of oxidative insults, such as stroke.


Subject(s)
Fibroblast Growth Factor 2/pharmacology , Fibroblast Growth Factors/pharmacology , Hippocampus/drug effects , Neurons/drug effects , Neuroprotective Agents/pharmacology , Oxidative Stress , Animals , Cells, Cultured , Fibroblast Growth Factor 8 , Hippocampus/cytology , Humans , Neuroblastoma/pathology , Rats , Tumor Cells, Cultured
9.
Neurosci Lett ; 262(3): 219-21, 1999 Mar 12.
Article in English | MEDLINE | ID: mdl-10218895

ABSTRACT

Glutamate excitotoxicity has been implicated in a variety of acute and chronic neurodegenerative diseases but early phase clinical trials with competitive antagonists at both N-methyl-D-aspartate (NMDA)-receptors and alpha-amino-3-hydroxy-5-methyl-isoxazolepropionate (AMPA) receptors have been disappointing. A family of atypical 2,3 benzodiazepines, exemplified by GYKI 52466, have been described recently which function as non-competitive AMPA-receptor antagonists. We have investigated the neuroprotective efficacy of LY303070 and LY300164, two analogs of GYKI-52466, in an embryonic rat hippocampal culture model of non-NMDA receptor-mediated excitotoxicity using kainic acid (KA) as an agonist at the AMPA/KA receptor. Overnight treatment with 500 microM KA resulted in prominent neuronal excitotoxicity as assessed by lactate dehydrogenase efflux. LY300164 and LY303070 attenuated KA-excitotoxicity in a dose-dependent manner with IC50s of 4 and 2 microM, respectively. In contrast, their stereoisomers, LY300165 and LY303071 showed no neuroprotection at concentrations up to 25 microM. In addition, AMPA-mediated excitotoxicity in cyclothiazide pre-treated cultures was also completely blocked by LY303070. Finally, neuroprotection by this class of 2,3 benzodiazepines was not influenced by antagonism of the classical benzodiazepine receptor. LY303070 and LY300164 represent novel non-competitive AMPA-receptor antagonists which may offer unique advantages in the clinic over competitive AMPA-receptor antagonists.


Subject(s)
Benzodiazepines/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Flumazenil/pharmacology , Hippocampus/cytology , Kainic Acid/pharmacology , Neurons/drug effects , Neuroprotective Agents/pharmacology , Receptors, AMPA/physiology , Receptors, N-Methyl-D-Aspartate/physiology , Animals , Cell Survival , Cells, Cultured , Fetus , Hippocampus/metabolism , L-Lactate Dehydrogenase , Neurons/cytology , Neurons/physiology , Rats , Rats, Sprague-Dawley , Receptors, AMPA/antagonists & inhibitors , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology
10.
J Neurochem ; 72(3): 1146-53, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10037487

ABSTRACT

The amyloid beta-peptide (A beta) is a major component of the neuritic plaques that are a defining histological characteristic of Alzheimer's disease. A beta can be directly toxic and pro-inflammatory to cells in vitro. Numerous reports have shown that oxidative damage and reactive oxygen species play a role in A beta-mediated neurotoxicity. 8-Epiprostaglandin F2alpha (8-isoprostane) is a well characterized product of lipid peroxidation that is formed nonenzymatically in cell membranes following an oxidative insult. We report a time- and concentration-dependent increase in 8-isoprostane levels in rat hippocampal cultures treated with A beta(1-40) or hydrogen peroxide. As evidence that 8-isoprostane production is part of an A beta toxic pathway, alkaline-treated peptide, which shows minimal toxic activity, resulted in greatly attenuated 8-isoprostane production. Although the increase in 8-isoprostane levels preceded cell death, exogenously added 8-isoprostane had no cytotoxic effects. The antioxidants vitamin E and propyl gallate attenuated A beta-induced 8-isoprostane formation yet had no effect on A beta-induced lactate dehydrogenase release. Neither vitamin E nor propyl gallate had any effect on A beta's ability to adopt a beta-pleated sheet structure and deposit on cells as determined by thioflavine S fluorescence. We conclude that 8-isoprostane is an indicator of A beta-induced damage but not necessarily a mediator of A beta-induced neurotoxicity. Also, 8-isoprostane could be a useful marker for assessing oxidative damage in the CNS.


Subject(s)
Amyloid beta-Peptides/metabolism , Dinoprost/analogs & derivatives , Oxidative Stress/physiology , Peptide Fragments/metabolism , Amyloid beta-Peptides/chemistry , Amyloid beta-Peptides/toxicity , Animals , Antioxidants/pharmacology , Benzothiazoles , Biomarkers , Cell Survival/drug effects , Cells, Cultured , Dinoprost/metabolism , F2-Isoprostanes , Fluorescent Dyes , Hippocampus/cytology , Hippocampus/embryology , Hippocampus/metabolism , Hydrogen Peroxide/toxicity , Kinetics , L-Lactate Dehydrogenase/metabolism , Lipid Peroxidation/drug effects , Neurons/drug effects , Neurons/metabolism , Oxidants/toxicity , Peptide Fragments/chemistry , Peptide Fragments/toxicity , Protein Conformation , Rats , Thiazoles
11.
J Neurochem ; 72(3): 1154-60, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10037488

ABSTRACT

The compound LY231617 [2,6-bis(1,1-dimethylethyl)-4-[[(1-ethyl)amino]methyl]phenol hydrochloride] has been reported to afford significant neuroprotection against hydrogen peroxide (H2O2)-induced toxicity in vitro and global ischemia in vivo. We now report on further mechanistic studies of H2O2 toxicity and protection by LY231617. Brief exposure to H2O2 (15 min) elicited an oxidative insult comparable with that generated by overnight treatment. H2O2-mediated cellular degeneration was characterized using lactate dehydrogenase (LDH) release, changes in total glutathione, and a new marker of oxidative stress, 8-epiprostaglandin F2alpha (8-isoprostane). LY231617 attenuated H2O2-mediated degeneration under a variety of exposure conditions, including a more clinically relevant posttreatment paradigm. Levels of 8-isoprostane paralleled LDH release under various treatment paradigms of 100 microM H2O2 +/- 5 microM drug. In contrast, despite affording significant protection, LY231617 had modest to no effects on cellular levels of glutathione. Taken together, these results are consistent with a membrane site of action for LY231617 and suggest that the compound affords cytoprotection via its antioxidant properties.


Subject(s)
Antioxidants/pharmacology , Butylated Hydroxytoluene/analogs & derivatives , Hydrogen Peroxide/antagonists & inhibitors , Oxidants/antagonists & inhibitors , Animals , Buthionine Sulfoximine/pharmacology , Butylated Hydroxytoluene/pharmacology , Cell Survival/drug effects , Culture Techniques , Dinoprost/analogs & derivatives , Dinoprost/metabolism , Enzyme Inhibitors/pharmacology , F2-Isoprostanes , Glutathione/metabolism , Hippocampus/cytology , Hippocampus/drug effects , Hippocampus/metabolism , Hydrogen Peroxide/metabolism , Hydrogen Peroxide/toxicity , Kinetics , L-Lactate Dehydrogenase/metabolism , Neurons/drug effects , Neurons/metabolism , Oxidants/toxicity , Rats , Rats, Sprague-Dawley
12.
Brain Res Mol Brain Res ; 42(1): 145-8, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8915593

ABSTRACT

Sulfated glycoprotein-2 (SGP-2) is a secreted glycoprotein that along with GFAP has emerged as a prominent molecular marker of neurodegeneration. In the present study, we have evaluated further the relationship between SGP-2, GFAP and neurodegeneration, by examining the effects of LY231617, a potent antioxidant, on expression of SGP-2 and GFAP following four vessel occlusion (4VO). GFAP and SGP-2 RNA levels increased several fold in hippocampus and caudate nucleus in response to 30 min of 4VO. LY231617 treatment markedly attenuated the induction of GFAP RNA in both hippocampus and caudate nucleus, consistent with the significant neuroprotection observed histologically. In contrast, LY231617 treatment blunted SGP-2 RNA expression only in the hippocampus; SGP-2 RNA expression in caudate nucleus was similar to vehicle-treated 4VO, despite the marked attenuation of neuronal damage in both areas by LY231617. These data suggest region-specific differential regulation of SGP-2 and GFAP RNA induction.


Subject(s)
Antioxidants/therapeutic use , Butylated Hydroxytoluene/analogs & derivatives , Ischemic Attack, Transient/drug therapy , Molecular Chaperones , Nerve Tissue Proteins/genetics , Neuroprotective Agents/therapeutic use , RNA, Messenger/biosynthesis , Animals , Biomarkers/chemistry , Butylated Hydroxytoluene/therapeutic use , Caudate Nucleus/blood supply , Caudate Nucleus/metabolism , Clusterin , Constriction , Glial Fibrillary Acidic Protein/genetics , Glycoproteins/genetics , Hippocampus/blood supply , Hippocampus/metabolism , Ischemic Attack, Transient/metabolism , Male , Nerve Degeneration/physiology , Rats , Rats, Wistar
13.
J Neurochem ; 67(4): 1595-606, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8858944

ABSTRACT

H2O2 and free radical-mediated oxidative stresses have been implicated in mediating amyloid beta (1-40) [A beta (1-40)] neurotoxicity to cultured neurons. In this study, we confirm that addition of the H2O2-scavenging enzyme catalase protects neurons in culture against A beta-mediated toxicity; however, it does so by a mechanism that does not involve its ability to scavenge H2O2. A beta-mediated elevation in intracellular H2O2 production is suppressed by addition of a potent H2O2 scavenger without any significant neuroprotection. Three intracellular biochemical markers of H2O2-mediated oxidative stress were unchanged by A beta treatment: (a) glyceraldehyde-3-phosphate dehydrogenase activity, (b) hexose monophosphate shunt activity, and (c) glucose oxidation via the tricarboxylic acid cycle. lonspray mass spectra of A beta in the incubation medium indicated that A beta itself is an unlikely source of reactive oxygen species. In this study we demonstrate that intracellular ATP concentration is compromised during the first 24-h exposure of neurons to A beta. Our results challenge a pivotal role for H2O2 generation in mediating A beta toxicity, and we suggest that impairment of energy homeostasis may be a more significant early factor in the neurodegenerative process.


Subject(s)
Amyloid beta-Peptides/pharmacology , Cerebral Cortex/metabolism , Glucose/metabolism , Hydrogen Peroxide/metabolism , Neurons/metabolism , Oxazines , Oxidative Stress , Peptide Fragments/pharmacology , Xanthenes , Adenosine Triphosphate/metabolism , Analysis of Variance , Animals , Benzothiazoles , Catalase/antagonists & inhibitors , Cell Survival , Cells, Cultured , Coloring Agents , Fetus , Fluoresceins , Free Radical Scavengers , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Glycolysis/drug effects , Glyoxylates/pharmacology , L-Lactate Dehydrogenase , Neurons/drug effects , Neurotoxins/pharmacology , Rats , Reactive Oxygen Species/metabolism , Thiazoles
14.
J Neurochem ; 67(3): 1324-7, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8752142

ABSTRACT

Clusterin is a secreted glycoprotein that is markedly induced in many disease states and after tissue injury. In the CNS, clusterin expression is elevated in neuropathological conditions such as Alzheimer's disease (AD), where it is found associated with amyloid-beta (A beta) plaques. Clusterin also coprecipitates with A beta from CSF, suggesting a physiological interaction with A beta. Given this interaction with A beta, the goal of this study was to determine whether clusterin could modulate A beta neurotoxicity. A mammalian recombinant source of human clusterin was obtained by stable transfection of hamster kidney fibroblasts with pADHC-9, a full-length human cDNA clone for clusterin. Recombinant clusterin obtained from this cell line, as well as a commercial source of native clusterin purified from serum, afforded dose-dependent neuroprotection against A beta (1-40) when tested in primary rat mixed hippocampal cultures. Clusterin afforded substoichiometric neuroprotection against several lots of A beta (1-40) but not against H2O2 or kainic acid excitotoxicity. These results suggest that the elevated expression of clusterin found in AD brain may have effects on subsequent amyloid-beta plaque pathology.


Subject(s)
Amyloid beta-Peptides/toxicity , Complement Inactivator Proteins/physiology , Glycoproteins/physiology , Molecular Chaperones , Neurotoxins/toxicity , Animals , Cell Line/physiology , Clusterin , Complement Inactivator Proteins/pharmacology , Cricetinae , Gene Expression/physiology , Glycoproteins/pharmacology , Hippocampus/cytology , Humans , Nerve Tissue Proteins/pharmacology , Nerve Tissue Proteins/physiology , Neuroprotective Agents/pharmacology , Rats , Transfection
15.
J Neural Transm (Vienna) ; 103(8-9): 905-16, 1996.
Article in English | MEDLINE | ID: mdl-9013384

ABSTRACT

Glutamate receptor-mediated excitotoxicity is linked to the activation of multiple receptors including those activated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), N-methyl-D-aspartate (NMDA), and kainate. In this study, the novel glutamate receptor antagonist, as its active isomer (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]-decahyd roisoquinoline-3- carboxylic acid ((-)LY293558) and it's +/- racemate (LY215490), was examined for neuroprotectant effects against excitotoxic injury in vitro and in vivo. This agent selectively protected against AMPA and kainate injury in cultured primary rat hippocampal neurons, an in vivo rat striatal neurotoxicity model, and against agonist-evoked seizures in mice. Thus, (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydr -oisguino-line-3-carboxylic acid represents a novel receptor selective and potent systemically active AMPA/kainate receptor antagonist for exploring neuroprotection via non-NMDA receptor mechanisms.


Subject(s)
Excitatory Amino Acid Antagonists/pharmacology , Isoquinolines/pharmacology , Neuroprotective Agents/pharmacology , Receptors, AMPA/antagonists & inhibitors , Receptors, Kainic Acid/antagonists & inhibitors , Tetrazoles/pharmacology , Animals , Cells, Cultured , Kainic Acid/toxicity , Male , Mice , Mice, Inbred Strains , Rats , Rats, Sprague-Dawley , Seizures/chemically induced , Seizures/drug therapy , Stereoisomerism , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/toxicity
16.
Proc Natl Acad Sci U S A ; 92(23): 10738-41, 1995 Nov 07.
Article in English | MEDLINE | ID: mdl-7479875

ABSTRACT

Neurodegenerative processes in Alzheimer disease (AD) are thought to be driven in part by the deposition of amyloid beta (A beta), a 39- to 43-amino acid peptide product resulting from an alternative cleavage of amyloid precursor protein. Recent descriptions of in vitro neurotoxic effects of A beta support this hypothesis and suggest toxicity might be mediated by A beta-induced neuronal calcium disregulation. In addition, it has been reported that "aging" A beta results in increased toxic potency due to peptide aggregation and formation of a beta-sheet secondary structure. In addition, A beta might also promote neuropathology indirectly by activating immune/inflammatory pathways in affected areas of the brain (e.g., cortex and hippocampus). Here we report that A beta can modulate cytokine secretion [interleukins 6 and 8 (IL-6 and IL-8)] from human astrocytoma cells (U-373 MG). Freshly prepared and aged A beta modestly stimulated IL-6 and IL-8 secretion from U-373 MG cells. However, in the presence of interleukin-1 beta (IL-1 beta), aged, but not fresh, A beta markedly potentiated (3- to 8-fold) cytokine release. In contrast, aged A beta did not potentiate substance P (NK-1)- or histamine (H1)-stimulated cytokine production. Further studies showed that IL-1 beta-induced cytokine release was potentiated by A beta-(25-35), while A beta-(1-16) was inactive. Calcium disregulation may be responsible for the effects of A beta on cytokine production, since the calcium ionophore A23187 similarly potentiated IL-1 beta-induced cytokine secretion and EGTA treatment blocked either A beta or A23187 activity. Thus, chronic neurodegeneration in AD-affected brain regions may be mediated in part by the ability of A beta to exacerbate inflammatory pathways in a conformation-dependent manner.


Subject(s)
Amyloid beta-Peptides/pharmacology , Astrocytes/metabolism , Interleukin-1/pharmacology , Interleukins/metabolism , Peptide Fragments/pharmacology , Alzheimer Disease/etiology , Astrocytes/drug effects , Astrocytoma , Calcium/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Encephalitis/etiology , Humans , Interleukin-6/metabolism , Interleukin-8/metabolism , Protein Conformation , Tumor Cells, Cultured
18.
Neurosci Lett ; 177(1-2): 162-4, 1994 Aug 15.
Article in English | MEDLINE | ID: mdl-7824173

ABSTRACT

Human cortical neuronal cell lines HCN-1A and HCN-2 are killed for following exposure of the differentiated cells to amyloid beta-peptide(1-40), a component of senile plaques and other amyloid deposits in brains from Alzheimer's patients. We present a model of A beta toxicity uncomplicated by the presence of other cell types that can be used to address the mechanism of A beta neurotoxicity. This model will be useful in the evaluation of neuroprotective compounds which may attenuate cortical neuronal loss in Alzheimer's disease.


Subject(s)
Amyloid beta-Peptides/toxicity , Neurons/drug effects , Peptide Fragments/toxicity , Biomarkers , Cell Death , Cell Line , Child , Child, Preschool , Female , Humans , Infant
19.
Mol Pharmacol ; 45(3): 373-9, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8145724

ABSTRACT

Amyloid beta peptide (A beta), the major protein constituent of senile plaques in patients with Alzheimer's disease, is believed to facilitate the progressive neurodegeneration that occurs in the latter stages of this disease. Early attempts to characterize the structure-activity relationship of A beta toxicity in vitro were compromised by the inability to reproducibly elicit A beta-dependent toxicity across different lots of chemically equivalent peptides. In this study we used CD spectroscopy to demonstrate that A beta secondary structure is an important determinant of A beta toxicity. Solubilized A beta was maximally toxic when the peptide adopted a beta-sheet conformation. Three of the four A beta lots tested had a random coil conformation and were weakly toxic or inactive, whereas the single A beta lot exhibiting toxic activity at low peptide concentrations had significant beta-sheet structure. Incubation of the weakly toxic A beta lots in aqueous stock solutions for several days before use induced a time-dependent conformational transition from random coil to beta-sheet and increased A beta toxicity in three different toxicity assays. Furthermore, the secondary structure of preincubated A beta was dependent upon peptide concentration and pH, so that beta-sheet structures were attenuated when peptide solutions were diluted or buffered at neutral and basic pH. Our data could explain some of the variable toxic activity that has been associated with A beta in the past and provide additional support for the hypothesis that A beta can have a causal role in the molecular neuropathology of Alzheimer's disease.


Subject(s)
Amyloid beta-Peptides/chemistry , Neurons/drug effects , Protein Structure, Secondary , Amyloid beta-Peptides/toxicity , Animals , Cell Survival/drug effects , Cells, Cultured , Circular Dichroism , Hydrogen-Ion Concentration , Neurons/chemistry , Neurons/cytology , Rats
20.
Brain Res ; 637(1-2): 97-105, 1994 Feb 21.
Article in English | MEDLINE | ID: mdl-8180824

ABSTRACT

Calcium-sensitive cytosolic phospholipase A2 (cPLA2) is responsible for receptor-mediated liberation of arachidonic acid, and thus plays an important role in the initiation of the inflammatory lipid-mediator cascade generating eicosanoids and platelet-activating factor. In this study we have investigated the cellular distribution of cPLA2 in brain using a monoclonal antibody raised against cPLA2 to immunostain tissue sections of human cerebral cortex. We have localized cPLA2 in astrocytes of the gray matter. Colocalization with glial fibrillary acidic protein (GFAP) confirmed that cPLA2 is associated predominantly with protoplasmic astrocytes. Astrocytes of the white matter, on the other hand, were not immunoreactive. In experiments using different human astrocytoma cell lines we found that cPLA2 can be immunochemically localized in UC-11 MG cells, but cannot be detected in U-373 MG cells. This finding is consistent with the observation that cPLA2 mRNA as well as cPLA2 enzymatic activity can be readily measured in UC-11 MG astrocytoma cells, yet cannot be detected in U-373 MG cells. Our data suggest that the astrocyte is a primary source of cPLA2 in the brain and provide further evidence for the importance of this cell type in inflammatory processes in the brain.


Subject(s)
Astrocytes/enzymology , Brain/enzymology , Calcium/physiology , Cytosol/enzymology , Phospholipases A/metabolism , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/immunology , Astrocytoma/enzymology , Brain/cytology , Brain Neoplasms/enzymology , Female , Glial Fibrillary Acidic Protein/immunology , Glial Fibrillary Acidic Protein/metabolism , Humans , Immunohistochemistry , Male , Middle Aged , Paraffin Embedding , Phospholipases A2 , Polymerase Chain Reaction , RNA, Messenger/biosynthesis , Transcription, Genetic , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...